Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients
<h3>Background:</h3><p dir="ltr">There has been a significant improvement in both our understanding and therapeutic choices available to clinicians for the management of cancer associated thrombosis (CAT). Even with the recent publication of a systematic review and landma...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , , |
| منشور في: |
2020
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513554920505344 |
|---|---|
| author | Mohammed ibn-Mas’ud Danjuma (20278119) |
| author2 | Mouhand F.H. Mohamed (16932579) Mohamad Nabil ElShafei (10223507) Haajra Fatima (9376835) Shaikha Al Shokri (18131404) Sara Mohamed (5961536) Ibrahim Yusuf Abubeker (20278122) Anand Kartha (9658520) Abdel-Naser Elzouki (9376853) Mohamed Gaafar Hussein Mohamedali (16316289) Yahya Mahgboub (20278125) Mubarak Bidmos (20278128) |
| author2_role | author author author author author author author author author author author |
| author_facet | Mohammed ibn-Mas’ud Danjuma (20278119) Mouhand F.H. Mohamed (16932579) Mohamad Nabil ElShafei (10223507) Haajra Fatima (9376835) Shaikha Al Shokri (18131404) Sara Mohamed (5961536) Ibrahim Yusuf Abubeker (20278122) Anand Kartha (9658520) Abdel-Naser Elzouki (9376853) Mohamed Gaafar Hussein Mohamedali (16316289) Yahya Mahgboub (20278125) Mubarak Bidmos (20278128) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohammed ibn-Mas’ud Danjuma (20278119) Mouhand F.H. Mohamed (16932579) Mohamad Nabil ElShafei (10223507) Haajra Fatima (9376835) Shaikha Al Shokri (18131404) Sara Mohamed (5961536) Ibrahim Yusuf Abubeker (20278122) Anand Kartha (9658520) Abdel-Naser Elzouki (9376853) Mohamed Gaafar Hussein Mohamedali (16316289) Yahya Mahgboub (20278125) Mubarak Bidmos (20278128) |
| dc.date.none.fl_str_mv | 2020-04-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1097/md.0000000000019679 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Comparative_effectiveness_and_safety_of_direct-acting_oral_anticoagulants_DOACS_for_the_reduction_of_recurrent_venous_thromboembolism_in_cancer_patients/27824544 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences cancer associated thrombosis cancer thrombosis DOAC DVT NOAC novel oral anticoagulant pulmonary embolism |
| dc.title.none.fl_str_mv | Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background:</h3><p dir="ltr">There has been a significant improvement in both our understanding and therapeutic choices available to clinicians for the management of cancer associated thrombosis (CAT). Even with the recent publication of a systematic review and landmark trials demonstrating the non-inferiority of DOACS-based anticoagulation strategy compared to the standard of care in patients with CAT, there is unresolved uncertainty regarding the exact hierarchy of risks and effectiveness of various DOAC analogues in these cohorts of patients.</p><h3>Method:</h3><p dir="ltr">We will carry out a network meta-analyses, utilizing a novel generalized pairwise methodology to generate direct and indirect comparisons between the various DOAC analogues. We will search the following databases for studies that satisfies pre-specified inclusions criteria; these include PubMed, EMBASE, Cochrane library, Clinicaltrials.gov, conference abstracts among other sources. The primary efficacy and safety outcomes are recurrent VTE and major hemorrhagic events, respectively. Two reviewers will Search the databases independently with the view to identify studies that meet eligibility criteria. The methodological quality of the included studies will be determined using a recently validated risk of bias assessment tool.</p><h3>Results:</h3><p dir="ltr">We expect that the result of this review will ascertain the hierarchy of risks and effectiveness of various DOAC analogues in patients with CAT.</p><h3>Conclusion:</h3><p dir="ltr">Results of this review will assist in informed decisions making regarding therapeutic guidelines of DOAC in CAT.</p><h2>Other Information</h2><p dir="ltr">Published in: Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0" target="_blank">http://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1097/md.0000000000019679" target="_blank">https://dx.doi.org/10.1097/md.0000000000019679</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_f6a8883a8a1a0e161c771dc94174d99f |
| identifier_str_mv | 10.1097/md.0000000000019679 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/27824544 |
| publishDate | 2020 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patientsMohammed ibn-Mas’ud Danjuma (20278119)Mouhand F.H. Mohamed (16932579)Mohamad Nabil ElShafei (10223507)Haajra Fatima (9376835)Shaikha Al Shokri (18131404)Sara Mohamed (5961536)Ibrahim Yusuf Abubeker (20278122)Anand Kartha (9658520)Abdel-Naser Elzouki (9376853)Mohamed Gaafar Hussein Mohamedali (16316289)Yahya Mahgboub (20278125)Mubarak Bidmos (20278128)Biomedical and clinical sciencesOncology and carcinogenesisPharmacology and pharmaceutical sciencescancer associated thrombosiscancer thrombosisDOACDVTNOACnovel oral anticoagulantpulmonary embolism<h3>Background:</h3><p dir="ltr">There has been a significant improvement in both our understanding and therapeutic choices available to clinicians for the management of cancer associated thrombosis (CAT). Even with the recent publication of a systematic review and landmark trials demonstrating the non-inferiority of DOACS-based anticoagulation strategy compared to the standard of care in patients with CAT, there is unresolved uncertainty regarding the exact hierarchy of risks and effectiveness of various DOAC analogues in these cohorts of patients.</p><h3>Method:</h3><p dir="ltr">We will carry out a network meta-analyses, utilizing a novel generalized pairwise methodology to generate direct and indirect comparisons between the various DOAC analogues. We will search the following databases for studies that satisfies pre-specified inclusions criteria; these include PubMed, EMBASE, Cochrane library, Clinicaltrials.gov, conference abstracts among other sources. The primary efficacy and safety outcomes are recurrent VTE and major hemorrhagic events, respectively. Two reviewers will Search the databases independently with the view to identify studies that meet eligibility criteria. The methodological quality of the included studies will be determined using a recently validated risk of bias assessment tool.</p><h3>Results:</h3><p dir="ltr">We expect that the result of this review will ascertain the hierarchy of risks and effectiveness of various DOAC analogues in patients with CAT.</p><h3>Conclusion:</h3><p dir="ltr">Results of this review will assist in informed decisions making regarding therapeutic guidelines of DOAC in CAT.</p><h2>Other Information</h2><p dir="ltr">Published in: Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0" target="_blank">http://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1097/md.0000000000019679" target="_blank">https://dx.doi.org/10.1097/md.0000000000019679</a></p>2020-04-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1097/md.0000000000019679https://figshare.com/articles/journal_contribution/Comparative_effectiveness_and_safety_of_direct-acting_oral_anticoagulants_DOACS_for_the_reduction_of_recurrent_venous_thromboembolism_in_cancer_patients/27824544CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/278245442020-04-01T00:00:00Z |
| spellingShingle | Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients Mohammed ibn-Mas’ud Danjuma (20278119) Biomedical and clinical sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences cancer associated thrombosis cancer thrombosis DOAC DVT NOAC novel oral anticoagulant pulmonary embolism |
| status_str | publishedVersion |
| title | Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients |
| title_full | Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients |
| title_fullStr | Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients |
| title_full_unstemmed | Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients |
| title_short | Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients |
| title_sort | Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients |
| topic | Biomedical and clinical sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences cancer associated thrombosis cancer thrombosis DOAC DVT NOAC novel oral anticoagulant pulmonary embolism |